Retinal Diseases – Talk Bio

Atsena reels in $150M to advance work on ocular gene therapies

3 weeks ago talkbio0Tagged Atsena, ATSN-101, ATSN-201, Blindness, Cloning Vectors, Dependovirus, Hereditary, Retinal Diseases, Retinoschisis, Juvenile, X-Linked, United States Food and Drug Administration

Atsena, Retinoschisis, Juvenile, X-Linked, United States Food and Drug Administration, Dependovirus, Cloning Vectors, Hereditary, Retinal Diseases, Blindness, ATSN-201, ATSN-101

Regeneron Expands Ophthalmology Portfolio with Acquisition of UK-Based Biotech Oxular

4 months ago talkbio0Tagged Acquisition, biotech, Drug Delivery Systems, Ophthalmology specialty, Oxular, Regeneron, Retinal Diseases, Technology

Regeneron, Oxular, Biotech Acquisition, Ophthalmology, Retinal Disorders, Drug Delivery Technology

Ocuphire Pharma Acquires Opus Genetics, Expanding into Inherited Retinal Disease Gene Therapies

6 months ago talkbio0Tagged Acquisition, Biological Factors, gene therapy, Hereditary, IRDs, Ocuphire Pharma, ophthalmic treatments, Opus, Retinal Diseases, Science of genetics

Ocuphire Pharma, Opus Genetics, gene therapy, inherited retinal diseases (IRDs), merger, acquisition, biopharmaceutical, ophthalmic treatments

Revolutionary Oral Treatment for Retinal Disease Shows Promising Results in Phase II Trials

11 months ago talkbio0Tagged Oral treatment, Phase 2 Clinical Trials, Retinal Diseases, Revolutionary, Rezolutes

Retinal disease, oral treatment, Phase II trials, revolutionary, promising results, Rezolutes.